Both agents can lead to Stevens–Johnson Syndrome (SJS), particularly in those with increased genetic risk such people of Asian descent, and it is recommended that patients at risk be tested for HLA-B*1502 and HLA-A*31:01 haplotype before initiating therapy due to a 10-fold increased risk of SJS. The gene discussed is HLA-A; the disease is Schwartz-Jampel syndrome.